Eli Lilly hikes sales outlook on obesity drug demand
Left 50%
Center 0%
Right 50%
1 left · 0 center · 1 right
What happened
Eli Lilly reported third-quarter results on Thursday that exceeded Wall Street estimates, posting adjusted earnings of $7.48 per share and revenue of $24.40 billion, versus expectations of $6.26 and $22.61 billion. Mounjaro sales rose 65% to $10.72 billion worldwide and Zepbound sales rose 49% to $5.35 billion; U.S. revenue climbed 34% on a 41% increase in volume, partly offset by a 7% drop in realized prices. The company raised its full-year sales outlook and shares rose after the report, while Foundayo, the oral obesity pill that launched in the United States in April, took in $184 million versus estimates of about $229 million. Lilly cited demand and Medicare’s July move to cover GLP-1 drugs for weight loss under a temporary pilot; deal-related charges reduced reported profit guidance even as the firm said it raised underlying earnings guidance.
Sourcing check · Mostly on the record · 2 articles
1 of 2 articles cite a named source for the story. It was on the record from the first report.
What these terms mean and how they're counted
- On the record · names a source 1 of 2
- On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Dave Ricks
- Primary evidence · cites a document or data 2 of 2
- Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: earnings report, company guidance, market data
- Credits another outlet 0 of 2
- The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
- Unnamed sources 0 of 2
- The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
- How it developed
- When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 29, 14:34 UTC by CNBC, naming its source. First document in the first report, from CNBC (earnings report).
- Not counted 0
- Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out
Unpacked
Readers get two different sizes of the same raise. Right-leaning coverage treats Lilly's new forecast as a 1 percent lift that mainly soothed fears over cheap Medicare pricing, while left-leaning coverage reports a much larger sales hike plus a CEO claim that most eligible patients still go untreated. The New York Post flags a $50 monthly Medicare price as the investor worry that the raise had to overcome. CNBC instead shows prior sales guidance starting at $85 billion and carries the chief executive's case that the obesity market has barely been reached.
Left-leaning coverage hangs the raise on unused demand, while right-leaning coverage hangs it on surviving a profit scare. CNBC is the only side to carry the CEO calling remaining room for expansion "dramatic."
Will Medicare still cover these drugs, and at what price, once the pilot ends?
Bottom line
The same Lilly raise reads as a modest nudge past Medicare-price fears in the New York Post and as a still-untapped obesity boom in CNBC. Only CNBC carries the prior sales floor of $85 billion.
The receipts — 5 facts one side's coverage lacks
- 2026 revenue guidance raised to $91–92 billion from a previous range of $85–87 billion
- Over half a million patients are using the injections through Medicare
- Lower U.S. net prices followed a drug-pricing deal with the Trump administration
- CEO Dave Ricks estimates 3% to 10% of eligible patients access obesity care in the U.S.
- Medicare began covering GLP-1s for weight loss in July under a temporary pilot program
The Left View
CNBC framed the quarter as proof that Lilly’s obesity and diabetes franchise, and its lead over Novo Nordisk, “shows no signs of slowing down” despite lower U.S. net prices after a drug-pricing deal with the Trump administration last year. It highlighted CEO Dave Ricks’s claim that there is room for “dramatic” market expansion because he estimates only 3% to 10% of eligible U.S. patients access obesity care, and his remark that the Medicare pilot is “a program that’s really working.” The outlet stressed Lilly’s 63% U.S. market share versus Novo’s 36.6%, a 93% jump in Mounjaro sales outside the United States, and the conversion of profits into dealmaking such as an agreement to buy Merida Biosciences for autoimmune and allergic-disease treatments. On Foundayo, it noted the miss versus estimates but reported that U.S. prescriptions and new patients doubled from the prior quarter, with about 4 in 10 patients starting an oral obesity medicine choosing Foundayo.
The Right View
The New York Post treated the report as a market milestone, leading with “big, fat demand” for weight-loss drugs that sent Lilly shares to a record and a valuation of about $1.2 trillion to $1.3 trillion, versus Novo Nordisk at about $171 billion. It stressed that Mounjaro and Zepbound beat expectations by more than 5% and that more than half a million patients are using the injections through Medicare at $50 a month—a price investors feared would hurt profits, even though the annual revenue forecast still rose to $92 billion. The Post highlighted acquisitions of psychedelic drugmaker AtaiBeckley and vaccine firm Curevo as putting “dents in the profit outlook,” citing a 50-cent cut to forecasted profit and quoting investor Greg Halter that “They’re spending money so that they can make money down the road.” It also flagged Foundayo’s roughly 15% sales shortfall and trial data showing less weight loss than Novo’s oral Wegovy, while noting Lilly’s confidence in the U.K. and further European launches.
Our Take (balanced)
CNBC’s strongest argument is that unit demand is still outrunning price cuts and that the addressable market is largely untapped: the reported U.S. volume-versus-price split, international volume growth, and Ricks’s 3%–10% penetration estimate underwrite the claim of “dramatic” expansion, with the Medicare pilot offered as early evidence of broader access. The New York Post’s strongest argument is that the equity story is already priced for continued dominance—a roughly $1.3 trillion capitalization versus Novo’s $171 billion—while Medicare’s $50 monthly price, Foundayo’s miss against oral Wegovy, and acquisition charges that dented the profit outlook raise questions about earnings quality and duration. The central unresolved tension is whether still-early patient penetration and injectable volume growth will more than offset lower U.S. realized prices and deal-related hits, or whether the oral-pill shortfall and discounted Medicare channel show the boom’s profit trajectory is less assured than the stock’s record move implies.
2 sources
More stories
The week's bottom lines, in your inbox
One email a week: the five stories that mattered and what they actually mean. Free.